Table 1:

Demographics and preoperative data

Patients (n)23
Male/female (n)20/3
Mean age ± SD (years) (min–max)52.0 ± 13.2 (24.2–70.5)
NYHA class
 I12 (52.2%)
 II5 (21.7%)
 III6 (26.1%)
 IV0
Marfan syndrome (n)3 (13.0%)
Valve pathology
 Tricuspid (n)18 (78.3%)
 Bicuspid (n)5 (21.7%)
Takayasu arteritis (n)1 (4.3%)
Dimensions, maximal (mm)
 Aortic root51.4 ± 8.9
 Ascending aorta50.6 ± 10.0
Aortic valve regurgitation (n)
 0+2
 1+4
 2+6
 3+11
Mean ± SD2.1 ± 1.0
Patients (n)23
Male/female (n)20/3
Mean age ± SD (years) (min–max)52.0 ± 13.2 (24.2–70.5)
NYHA class
 I12 (52.2%)
 II5 (21.7%)
 III6 (26.1%)
 IV0
Marfan syndrome (n)3 (13.0%)
Valve pathology
 Tricuspid (n)18 (78.3%)
 Bicuspid (n)5 (21.7%)
Takayasu arteritis (n)1 (4.3%)
Dimensions, maximal (mm)
 Aortic root51.4 ± 8.9
 Ascending aorta50.6 ± 10.0
Aortic valve regurgitation (n)
 0+2
 1+4
 2+6
 3+11
Mean ± SD2.1 ± 1.0
Table 1:

Demographics and preoperative data

Patients (n)23
Male/female (n)20/3
Mean age ± SD (years) (min–max)52.0 ± 13.2 (24.2–70.5)
NYHA class
 I12 (52.2%)
 II5 (21.7%)
 III6 (26.1%)
 IV0
Marfan syndrome (n)3 (13.0%)
Valve pathology
 Tricuspid (n)18 (78.3%)
 Bicuspid (n)5 (21.7%)
Takayasu arteritis (n)1 (4.3%)
Dimensions, maximal (mm)
 Aortic root51.4 ± 8.9
 Ascending aorta50.6 ± 10.0
Aortic valve regurgitation (n)
 0+2
 1+4
 2+6
 3+11
Mean ± SD2.1 ± 1.0
Patients (n)23
Male/female (n)20/3
Mean age ± SD (years) (min–max)52.0 ± 13.2 (24.2–70.5)
NYHA class
 I12 (52.2%)
 II5 (21.7%)
 III6 (26.1%)
 IV0
Marfan syndrome (n)3 (13.0%)
Valve pathology
 Tricuspid (n)18 (78.3%)
 Bicuspid (n)5 (21.7%)
Takayasu arteritis (n)1 (4.3%)
Dimensions, maximal (mm)
 Aortic root51.4 ± 8.9
 Ascending aorta50.6 ± 10.0
Aortic valve regurgitation (n)
 0+2
 1+4
 2+6
 3+11
Mean ± SD2.1 ± 1.0
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close